ECCV
Eagle Point Credit Company Inc.
There isn't enough reported data to score ECCV yet.
JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
ECCV Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| N/A | |
| N/A |
ECCV's revenue and profitability are currently weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like ECCV.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
ECCV PE Valuation
ECCV has no meaningful PE right now: it lost money over the past year.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
ECCV Forward outlook
There aren't enough analyst estimates for ECCV to show an outlook.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
ECCV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.24 | -1227% |
| Q1 2026 | -$1.29 | -$0.89 |
| Q4 2025 | -$0.98 | -217% |
| Q3 2025 | $0.26 | -67% |
| Q2 2025 | $0.11 | -93% |
| Q1 2025 | -$0.40 | -123% |
| Q4 2024 | $0.84 | -50% |
| Q3 2024 | $0.78 | -48% |
ECCV has swung to a loss: it lost $1.24 per share over the past year, after a profit the year before.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over ECCV on earnings quality, reporting a profit while its opponent remains loss making.
ECCV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $31.4M | -45% |
| Q3 2025 | $52M | +10% |
| Q1 2025 | $57.7M | +41% |
| Q4 2024 | $49.5M | +26% |
| Q3 2024 | $47.1M | +31% |
| Q1 2024 | $40.8M | +32% |
| Q4 2023 | $39.4M | +21% |
| Q3 2023 | $36M | +19% |
ECCV's revenue has slid since its 2025 peak: −$63M last quarter, down 188% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -433% | -282 points |
| Q3 2025 | 75% | +1.5 points |
| Q2 2025 | 87% | N/A |
| Q1 2025 | -152% | -220 points |
| Q4 2024 | 65% | -7.4 points |
| Q3 2024 | 73% | +0.9 points |
| Q1 2024 | 69% | -9 points |
| Q4 2023 | 73% | -2.6 points |
ECCV's operating margin was −433% last quarter, down 498 points from the same quarter a year ago, near the bottom of its range since 2019.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM has the edge over ECCV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
ECCV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $34.8M | +17% |
| Q1 2026 | $29M | +6% |
| Q4 2025 | $30.3M | +24% |
| Q3 2025 | -$16.3M | -158% |
| Q2 2025 | $29.7M | +3.2% |
| Q1 2025 | $27.4M | +24% |
| Q4 2024 | $24.5M | +2% |
| Q3 2024 | $28.2M | +27% |
ECCV has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
ECCV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +480K shares |
| 1 year | +11% | +12.8M shares |
| 3 years | +112% | +70.2M shares |
| 5 years | +286% | +98.5M shares |
| Available history | +390% | +106M shares |
ECCV has 133M diluted shares, up 11% from a year ago, despite $63M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $57.9M |
| Q1 2026 | $4.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ECCV spent $63M buying back its own shares over the past year, after none the year before.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over ECCV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
ECCV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 7.6x | High |
| Q2 2025 | 4.8x | High |
| Q1 2024 | 1.8x | Healthy |
| Q4 2023 | 1.1x | Healthy |
| Q3 2023 | 1.8x | Healthy |
| Q2 2023 | 1.2x | Healthy |
| Q1 2023 | 2.1x | Moderate |
| Q4 2022 | 1.1x | Healthy |
ECCV's net debt is about 7.6 years of its operating earnings (EBITDA), up from 1.8 years a year ago. Net leverage isn't a meaningful measure for financial services companies like ECCV.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
ECCV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.4 | Neutral |
| Stochastic | 43.3 | Neutral |
ECCV's weekly RSI is 52 (neutral) and its Stochastic is 43 (neutral).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
ECCV PE vs Financial Services Sector
| Metric | ECCV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
ECCV has no meaningful PE right now: it lost money over the past year.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
ECCV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.2 | 0.1% below |
| 20 week MA | $24.1 | 0.2% above |
| 50 week MA | $23.9 | 1.1% above |
| 100 week MA | $23.5 | 2.8% above |
| 200 week MA | $22.9 | 5.6% above |
ECCV's trend is up, with a small recent dip: it's below only its 8-week average, and 5.6% above its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
ECCV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $24.3 | $21.0 | -13% |
| 2023 | $21.0 | $22.4 | +6.4% |
| 2024 | $22.4 | $22.7 | +1.6% |
| 2025 | $22.7 | $23.5 | +3.5% |
| 2026 YTD | $23.5 | $24.2 | +2.8% |
ECCV has finished higher in three of the last four years. It's up 2.8% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over ECCV on returns for 2026, with the stronger performance.